NCT06065345已完成不适用
BIOTRONIK- Pharmacokinetic Study of a Sirolimus Derivative-Coated Balloon (BRight DCB) in the Superficial Femoral and Proximal Popliteal Artery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Terminal Elimination Half-life (t1/2)
研究概览
简要总结
The BRight PK Study is a prospective, single-arm, open-label, non-blinded, non-randomized study, which goal is to assess the pharmacokinetic profile of the BRight drug-coated balloon at different time points after the balloon deployment.
The study will enroll a maximum of 10 patients at a single site in Australia
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject has provided written informed consent
- •The subject is willing to participate in the clinical investigation and to comply with the study procedures and follow-up visits
- •Lifestyle-limiting claudication or rest pain requiring treatment of superficial femoral (SFA) and/or proximal popliteal artery (PPA)
- •Age ≥ 18 years old
- •Rutherford-Becker Clinical Category of 2, 3 or 4
- •Target vessel reference diameter ≥5 mm and ≤ 6 mm (by visual estimation)
- •De novo lesion with >50% stenosis by operator visual estimate within the SFA and/or proximal popliteal arteries in a single limb.
- •Lesion must be located ≥ 1 cm below the Common Femoral Artery (CFA) bifurcation and terminate distally at ≥ 3 cm proximal to the knee joint (radiographic joint space).
- •Single lesion length ≤170 mm for de novo stenotic lesions, or ≤ 100 mm for occluded lesions (one long lesion or multiple serial lesions) by operator visual estimate. Notes: (1) Only 1 lesion per patient can be treated. Multiple serial lesions are allowed if they can be treated as a single lesion with a maximum of 2 balloons. (2) a non-occlusive lesion that includes a totally occluded segment along its length are eligible provided that the overall treated lesion length is ≤170 mm (with / or without an occluded segment not greater than 100 mm in length).
- •Successful guidewire crossing of lesion.
- •After pre-dilatation, the target lesion is ≤ 30% residual stenosis with no flow limiting dissection and treatable with a maximum of 2 balloons.
- •Inflow artery is patent, free from significant lesion stenosis (>50% stenosis considered significant) as confirmed by angiography.
- •Note: Where required, inflow iliac arteries (common and external iliac arteries only) must be successfully treated during the index procedure. Completion angiography must confirm successful treatment of inflow disease (≤50% residual stenosis, no distal embolization, and no Grade C or greater dissection) prior to pre-dilatation of the target lesion. Drug-eluting devices are not allowed for treatment of the occluded inflow iliac arteries.
- •Patency of the popliteal segments P2 and P3 with at least 1 patent infrapopliteal run-off vessel (that may have a stenosis of less than 50% not interfering with the outflow to the pedal arch) to the ankle in continuity with the native femoropopliteal artery, in the target limb confirmed at baseline. (Note: treatment of outflow disease is permitted. Drug-eluting devices are not allowed for outflow treatment)
排除标准
- •Females who are pregnant, lactating, or intended to become pregnant, or males intending to father children during the study
- •Subject under current medication known to affect CYP3A4 metabolism, or consuming food or beverages that are known substrates of CYP3A4
- •Contraindication to dual anti-platelet therapy
- •Subject receiving chronic anticoagulation therapy (e.g. low molecular weight heparin, warfarin, or novel direct oral anticoagulants (N(D)OACs)) if the treatment cannot be interrupted 48 hours prior to the procedure
- •Known intolerance to study medications, Limus- like drug or contrast agents that in the opinion of the investigator could not be adequately pretreated
- •Current participation in an investigational drug or another device study
- •History of hemorrhagic stroke within 3 months
- •Patients with a history of Myocardial Infarction (MI) or thrombolysis within 30 days prior-index procedure
- •Previous or planned surgical or interventional procedure within 14 days before or 30 days after index procedure (successful treatment of the ipsilateral and contralateral iliac arteries is permitted during the index procedure. Drug-eluting devices are not allowed for treatment of the occluded inflow iliac arteries)
- •Prior endovascular treatment of the target lesion (e.g., POBA, DCB, BMS, DES, cutting balloons, scoring balloons, cryoplasty, thrombectomy, atherectomy, brachytherapy or laser devices)
- •Previous placement of a bypass graft proximal to the target lesion
- •Chronic renal insufficiency (eGFR < 30 mL/min within 72 hours prior to index procedure)
- •Patient requiring renal replacement therapy
- •No normal proximal arterial segment in which duplex ultrasound velocity ratios could be measured.
- •Subject is unable to walk without assistance (e.g. walker, cane).
- •Subject is receiving immunosuppressant therapy.
- •Subject has known or suspected active infection at the time of the index procedure.
- •Subject has platelet count < 100,000/mm3 or > 700,000/mm
- •Subject has white blood cell (WBC) count < 3,000/mm
- •Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
- •Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the index procedure.
- •Life expectancy less than 12 months due to other comorbidities, that in the investigators opinion, could limit subject ability to comply with the study required follow-up visits/procedure and threaten the study scientific integrity
- •Treatment of the contralateral limb during the same procedure or within 30 days following the study procedure (exclusive of the iliac arteries, which can be treated during the index procedure if no drug eluting technology is used)
- •Non femoral vascular access
- •Target lesion would require treatment with more than two BRight balloons
- •Known inadequate distal outflow
- •Acute or sub-acute thrombus in the target vessel
- •Aneurysmal target vessel
- •Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, brachytherapy) during the study procedure in the target lesion or target vessel
- •Presence of concentric calcification that precludes PTA pre-dilatation
- •Significant contralateral or ipsilateral common femoral disease that requires intervention during the index procedure
- •Persistent hemodynamically-significant stenosis following predilatation or residual stenosis of >30%, stent placement, or flow-limiting (Grade D or greater) dissection following pre-dilatation
- •In-stent restenosis
结局指标
主要结局
Terminal Elimination Half-life (t1/2)
时间窗: 0 to 24 hours
Apparent terminal elimination half-life, calculated as ln(2)/λz
Apparent volume of distribution at the terminal phase (Vz)
时间窗: 0 to 24 hours
Apparent volume of distribution at the terminal phase, calculated as CL/λz
Metabolic Ratio (MR)
时间窗: 0 to 24 hours
Metabolic ratio calculated as the molar concentration of sirolimus AUC0-inf to BIOtorcin AUC0-inf
AUC 0-inf
时间窗: 0 to 24 hours
Area under the drug concentration-time curve from time zero to infinity
Cmax
时间窗: 0 to 24 hours
Maximum observed drug concentration
Drug clearance (CL)
时间窗: 0 to 24 hours
Apparent total clearance, calculated as dose/AUC0-inf
AUC 0-t
时间窗: 0 to 24 hours
Area under the drug concentration-time curve, calculated using linear trapezoidal summation from time zero to time tlast, where tlast is the time of the last measurable concentration (Ct).
Terminal Elimination Rate Constant (λz)
时间窗: 0 to 24 hours
Apparent terminal elimination rate constant, calculated by linear regression of the terminal linear portion of the log concentration vs. time curve
tmax
时间窗: 0 to 24 hours
Time of the maximum drug concentration (obtained without interpolation). If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.
次要结局
- All-cause of death rate(1, 6 and 12 months post index procedure)
- Change in Ankle Brachial Index (ABI) as compared to baseline(1, 6 and 12 months post index procedure)
- Change in Walking Impairment Questionnaire (WIQ) as compared to baseline(1, 6 and 12 months post index procedure)
- Clinically-driven Target Vessel Revascularization (cd TVR) rate(1, 6 and 12 months post index procedure)
- Change in Rutherford Classification as compared to baseline(1, 6 and 12 months post index procedure)
- Acute procedural success(72 hours post procedure)
- Target limb major (above the ankle) and minor (below the ankle) amputation rate(1, 6 and 12 months post index procedure)
- Device success(during procedure)
- Acute technical success(during procedure)
- Major adverse event (MAE) rate(1, 6 and 12 months post index procedure)
- Clinically-driven Target Lesion Revascularization (cd TLR) rate(1, 6 and 12 months post index procedure)
- Target lesion Binary Restenosis rate(1, 6 and 12 months post index procedure)
- Target lesion Primary Patency rate(1, 6 and 12 months post index procedure)
- embolic event of the index limb rate(during procedure)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid TumorsRefractory Solid TumorsNCT02688881Samsung Medical Center6
已完成
3 期
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)Coronary Artery DiseaseNCT00232765Cordis Corporation1,058
已完成
不适用
The ILLUMINA Study. (ILLUMINA)Peripheral Arterial DiseaseNCT03510676CID - Carbostent & Implantable Devices100
已完成
1 期
A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese SubjectsHealthy Japanese VolunteersNCT03605082UCB Biopharma S.P.R.L.24
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT05205499Biotyx Medical (Shenzhen) Co., Ltd.1,059